Wegovy weight loss sustained for four years in trial, Novo Nordisk says

Patients taking Novo Nordisk's (NOVOb.CO) popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.

Novo presented the new long-term data at the European Congress on Obesity in Venice, Italy, gleaned from a large study for which much of the results had been published last year.